Via Cyte
Biotechnology, 5580 Morehouse Dr, San Diego, California, 92121, United States, 51-200 Employees
Phone Number: 85********
Who is VIACYTE
About ViaCyte ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control t...
Read More
-
Headquarters: 5580 Morehouse Dr, San Diego, California, 92121, United States
-
Date Founded: 1999
-
Employees: 51-200
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
ViaCyte Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding ViaCyte
Answer: ViaCyte's headquarters are located at 5580 Morehouse Dr, San Diego, California, 92121, United States
Answer: ViaCyte's phone number is 85********
Answer: ViaCyte's official website is https://viacyte.com
Answer: ViaCyte's revenue is $25 Million to $50 Million
Answer: ViaCyte's SIC: 2834
Answer: ViaCyte's NAICS: 325412
Answer: ViaCyte has 51-200 employees
Answer: ViaCyte is in Biotechnology
Answer: ViaCyte contact info: Phone number: 85******** Website: https://viacyte.com
Answer: About ViaCyte ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCytes product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates. About ViaCytes Pipeline The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCytes PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month